All Outputs (48)

IL-6 knockdown in a model of the human bone marrow, abrogates DNA damage induction in bystander cells post-chemotherapy induced cytokine release syndrome (2024)
Journal Article

Following infection or exposure to therapeutic agents, an aggressive immune response may result, termed cytokine storm (CS) or cytokine release syndrome. Here the innate immune system becomes uncontrolled, leading to serious consequences including po... Read More about IL-6 knockdown in a model of the human bone marrow, abrogates DNA damage induction in bystander cells post-chemotherapy induced cytokine release syndrome.

Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3 (2024)
Journal Article

In a screen of over 200 novel pyrazole compounds, ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl) phenyl)ureido)-1H-pyrazole-4-carboxylate (named GeGe-3) has emerged as a potential anticancer compound. GeGe-3 displays potent anti-angiogenic prope... Read More about Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3.

Going circular: history, present, and future of circRNAs in cancer. (2023)
Journal Article

To date, thousands of highly abundant and conserved single-stranded RNA molecules shaped into ring structures (circRNAs) have been identified. CircRNAs are multifunctional molecules that have been shown to regulate gene expression transcriptionally a... Read More about Going circular: history, present, and future of circRNAs in cancer..

SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia (2023)
Journal Article

Introduction: Dysregulated alternative splicing is a prominent feature of cancer. The inhibition and knockdown of the SR splice factor kinase SRPK1 reduces tumour growth in vivo. As a result several SPRK1 inhibitors are in development including SPHIN... Read More about SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia.

CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer (2021)
Journal Article

Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and o... Read More about CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer.

WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1 (2020)
Journal Article

Dysregulated alternative splicing plays a prominent role in all hallmarks of cancer. The splice factor kinase SRPK1 drives the activity of oncogenic splice factors such as SRSF1. SRSF1 in turn promotes the expression of splice isoforms that favour tu... Read More about WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer (2020)
Journal Article

Background: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefor... Read More about Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.

Abscisic acid induced a negative geotropic response in dark-incubated Chlamydomonas reinhardtii (2019)
Journal Article

© 2019, The Author(s). The phytohormone abscisic acid (ABA) plays a role in stresses that alter plant water status and may also regulate root gravitropism and hydrotropism. ABA also exists in the aquatic algal progenitors of land plants, but other th... Read More about Abscisic acid induced a negative geotropic response in dark-incubated Chlamydomonas reinhardtii.

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment (2019)
Journal Article

© 2019, International Society for Cellular Oncology. Purpose: Isothiocyanates elicit anticancer effects by targeting cancer stem cells (CSCs). Here, we tested the antitumor activity of phenethyl-isothiocyanate (PEITC), either alone or in combination... Read More about Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.

Altered VEGF splicing isoform balance in tumor endothelium involves activation of splicing factors Srpk1 and Srsf1 by the Wilms’ tumor suppressor Wt1 (2019)
Journal Article

Angiogenesis is one hallmark of cancer. Vascular endothelial growth factor (VEGF) is a known inducer of angiogenesis. Many patients benefit from antiangiogenic therapies, which however have limitations. Although VEGF is overexpressed in most tumors,... Read More about Altered VEGF splicing isoform balance in tumor endothelium involves activation of splicing factors Srpk1 and Srsf1 by the Wilms’ tumor suppressor Wt1.

The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties (2018)
Journal Article

© 2018 The oncogene ERG encodes an ETS family transcription factor and is implicated in blood, vascular, and bone development and in prostate, blood, and bone cancer. The ERG gene is alternatively spliced; of particular interest is its cassette exon... Read More about The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties.

Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention (2018)
Journal Article

© 2018 Elsevier B.V. Alternative splicing is a key process required for the regulation of gene expression in normal development and physiology. It is regulated by splice factors whose activities are in turn regulated by splice factor kinases and phos... Read More about Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention.

Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells (2018)
Journal Article

© 2018 The Author(s). Background: Mounting evidence suggests that one of the ways that cells adapt to hypoxia is through alternative splicing. The aim of this study was firstly to examine the effect of hypoxia on the alternative splicing of cancer as... Read More about Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.

The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells (2017)
Journal Article

© 2017, Spandidos Publications. All rights reserved. The oncogene ETS-related gene (ERG) encodes a transcription factor with roles in the regulation of haematopoiesis, angiogenesis, vasculogenesis, inflammation, migration and invasion. The ERG oncoge... Read More about The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells.

Residual ground-water levels of the neonicotinoid thiacloprid perturb chemosensing of Caenorhabditis elegans (2017)
Journal Article

© 2017, The Author(s). This study investigated the neurological effects of residual ground-water levels of thiaclopridon the non-target organism Caenorhabditis elegans. Nematodes treated with thiacloprid showed a dose-dependent and significantly incr... Read More about Residual ground-water levels of the neonicotinoid thiacloprid perturb chemosensing of Caenorhabditis elegans.

Insulin receptor isoform variations in prostate cancer cells (2016)
Journal Article

� 2016 Perks, Zielinska, Wang, Jarrett, Frankow, Ladomery, Bahl, Rhodes, Oxley and Holly. Men who develop prostate cancer (PCa) increasingly have one of the co-morbidities associated with a Western lifestyle that are characterized by hyperinsulinem... Read More about Insulin receptor isoform variations in prostate cancer cells.

Oligonucleotide-based systems: DNA, microRNAs, DNA/RNA aptamers (2016)
Journal Article

© 2016 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society. There are an increasing number of applications that have been developed for oligonucleotide-based biosensing systems in genetics and biomedicine. Oligonuc... Read More about Oligonucleotide-based systems: DNA, microRNAs, DNA/RNA aptamers.

The Scd6/Lsm14 protein xRAPB has properties different from RAP55 in selecting mRNA for early translation or intracellular distribution in Xenopus oocytes (2015)
Journal Article

© 2015 Elsevier B.V. Oocytes accumulate mRNAs in the form of maternal ribonucleoprotein (RNP) particles, the protein components of which determine the location and stability of individual mRNAs prior to translation. Scd6/Lsm14 proteins, typified by R... Read More about The Scd6/Lsm14 protein xRAPB has properties different from RAP55 in selecting mRNA for early translation or intracellular distribution in Xenopus oocytes.

The evolutionarily conserved multifunctional glycine-rich RNA-binding proteins play key roles in development and stress adaptation (2015)
Journal Article

© 2014 Scandinavian Plant Physiology Society. The class IV glycine-rich RNA-binding proteins are a distinct subgroup within the heterogenous superfamily of glycine-rich proteins (GRPs). They are distinguished by the presence of an RNA-binding domain... Read More about The evolutionarily conserved multifunctional glycine-rich RNA-binding proteins play key roles in development and stress adaptation.

Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer (2014)
Journal Article

© 2015 Macmillan Publishers Limited. All rights reserved. Angiogenesis is required for tumour growth and is induced principally by vascular endothelial growth factor A (VEGF-A). VEGF-A pre-mRNA is alternatively spliced at the terminal exon to produce... Read More about Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.